Autosomal Dominant Polycystic Kidney Disease Market is driven by Increasing Research and Development Activities
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a hereditary kidney disorder characterized by formation and enlargement of cysts within the kidneys that can lead to kidney failure if left untreated. Treatment of ADPKD involves controlling blood pressure and slowing kidney function decline with medications such as Angiotensin II receptor blockers and vasopressin receptor antagonists.
The Global Autosomal Dominant Polycystic Kidney Disease Market is estimated to be valued at USD 1.56 Bn in 2024 and is expected to reach USD 2.25 Bn by 2031, growing at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
The increasing prevalence of Autosomal Dominant Polycystic Kidney Disease Market along with rising awareness regarding treatment options is boosting the demand for ADPKD treatments globally. According to the estimates, around 12.5 million people across the world are affected by ADPKD.
Get more insights on: Autosomal Dominant Polycystic Kidney Disease Market
Get this Report in Japanese Language: 常染色体優性多発性嚢胞腎市場
Get this Report in Korean Language: 상염색체 우성 다낭성 신장 질환 시장
English
Arabic
Français
Español
Português
Türkçe
Dutch
Italiano
Russian
Romaian